The results from a new study of the multi-kinase inhibitor fexagratinib in mouse models are raising hopes that the therapy ...

Mapping cell types in MS lesions reveals unique tissue niches and interactions, offering insights into the molecular drivers of multiple sclerosis progression.

"Thus, progression is present in most, if not all, patients with multiple sclerosis, regardless of where they are ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

The prevalence of MS in Australia has been increasing at an accelerating rate in recent years, according to a report from MS Australia.

Biogen BIIB reported third-quarter 2024 adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $3.77. While earnings declined 6% year over year on a reported basis, it ...

TD Cowen analyst Tara Bancroft initiated coverage of TG Therapeutics (TGTX) with a Buy rating and $50 price target The company’s Briumvi ...

TD Cowen analyst Tara Bancroft maintained a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target of ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Solange Knowles has opened up about her “debilitating” battle with multiple autoimmune disorders. The “Losing You” singer revealed in the comments section of musician Shaun Ross ...